and Human Services (HHS)
EXPIRED
ROLE OF HORMONES AND GROWTH FACTORS IN PROSTATE CANCER
Release Date: August 7, 2000
RFA: DK-01-008
National Institute of Diabetes and Digestive and Kidney Diseases
(http://www.niddk.nih.gov/)
National Institute on Aging
(http://www.nih.gov/nia/)
National Cancer Institute
(http://www.nci.nih.gov/)
National Institute of Environmental Health Sciences
(http://www.niehs.nih.gov/)
Letter of Intent Receipt Date: 2/27/01
Application Receipt Date: 3/27/01
PURPOSE
This initiative is designed to explore the underlying mechanism(s) of
action of hormones and growth factors in the regulation of prostate
development, growth, and tumorigenesis. The focus will be on
fundamental studies of hormone and growth factor action including the
mechanisms of action of nuclear hormones, the role(s) of nuclear
accessory proteins and the signal transduction pathways important for
nuclear hormone action in prostate. Focus will also be on growth
factor action in prostate, including growth factors, binding proteins,
receptors and signal transduction pathways. Studies are also invited
that will examine the patterns of gene expression in the prostate in
vivo or in prostate cells in response to hormone or growth factor
action. Moreover, since there are some studies that indicate that
environmental factors also increase the risk for development of
prostate cancer, an additional focus will be on studies that will
explore the role of environmental factor(s) in affecting
hormonal/growth factor action in prostate. Finally, studies on the
development and potential use of hormone/growth factor analogs,
agonists, or antagonists with potential clinical utility to modify
prostate growth and tumor development and/or progression will be
encouraged.
HEALTHY PEOPLE 2010
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2010," a
PHS-led national activity for setting priority areas. {This RFA, ROLE
OF HORMONES AND GROWTH FACTORS IN PROSTATE CANCER, is related to the
priority area of hormonal carcinogenesis and prostate disease.
Potential applicants may obtain a copy of "Healthy People 2010" at
http://www.health.gov/healthypeople.
ELIGIBILITY REQUIREMENTS
Applications may be submitted by domestic and foreign for-profit and
nonprofit organizations, public and private, such as universities,
colleges, hospitals, laboratories, units of State and local
governments, and eligible agencies of the Federal government.
Racial/ethnic minority individuals, women, and persons with
disabilities are encouraged to apply as Principal Investigators.
MECHANISM OF SUPPORT
This RFA will use the National Institutes of Health (NIH) research
project grant (R01) and pilot and feasibility (R21) award mechanisms.
Only new (Type 1) grant submissions will be accepted for this
initiative. Amended and competing continuing applications will not be
accepted. Applications for research project grants (R01) may be
submitted for up to 4 years of support with first year direct cost
budgets of no more than $225,000. Applications for pilot and
feasibility (R21) awards may be submitted for up to two years with
first year direct cost budgets of no more than $100,000.
Responsibility for the planning, direction, and execution of the
proposed project will be solely that of the applicant. Except as
otherwise stated in this announcement, awards will be administered
under NIH grants policy as stated in the NIH Grants Policy Statement.
Specific application instructions have been modified to reflect
"MODULAR GRANT" and "JUST-IN-TIME" streamlining efforts being examined
by the NIH. Complete and detailed instructions and information on
Modular Grants can be found at
http://grants.nih.gov/grants/funding/modular/modular.htm.
Applicants from institutions that have a General Clinical Research
Center (GCRC) funded by the NIH National Center for Research Resources
may wish to identify the GCRC as a resource for conducting the proposed
research. In such a case, a letter of agreement from either the GCRC
program director or principal investigator should be included with the
application.
This RFA is a one-time solicitation. Future unsolicited competing
continuation applications will compete with all investigator-initiated
applications and be reviewed according to the customary peer review
procedures. Responsibility for the planning, direction, and execution
of the proposed project will be solely that of the applicant. The
total requested project period for applications submitted in response
to this RFA may not exceed four years (two for the R21). The
anticipated award date is September 28, 2001.
FUNDS AVAILABLE
For FY 2001, $3,000,000 will be committed by NIDDK to fund applications
submitted in response to this RFA. The NIA will commit $300,000, the
NCI will commit $1,000,000, and NIEHS will commit $300,000. Thus, a
total of $4,600,000 has been committed for FY 2001 to fund
approximately 20-25 grants, however, this funding level is dependent
upon the receipt of a sufficient number of applications of high
scientific merit. Although this program is provided for in the
financial plans of the NIDDK, NIA, NCI, and NIEHS, the award of grants
pursuant to this RFA is also contingent upon the availability of funds
for this purpose.
RESEARCH OBJECTIVES
Background
Although the prostate is clearly a sex steroid (Androgen) dependent
tissue, there is ample evidence to support roles for numerous other
nuclear and peptide hormones, as well as growth factors and cytokines
in the development of the tissue and the development and progression of
tumors arising from cells within the adult tissue. At a recent NIDDK
International Symposium on the Biology of Prostate Growth, data were
presented to show that factors such as the Insulin-like growth factor-I
(IGF-I), fibroblast growth factor (FGF), members of the erbB family,
and others, as well as their receptors and binding proteins, and other
small bioactive peptide hormones, have been implicated in development,
growth and differentiation of both the epithelial and the stromal
components of prostate. Furthermore, activation of peptide growth
factor receptors initiates signal transduction pathways leading to
change in cellular function and/or structure. In some cases of
aberrant prostate growth, the growth factor receptors are overexpressed
or otherwise dysregulated, or are constitutively activated. In other
cases, components of signal transduction pathways are overexpressed or
constitutively activated. Additionally, agents that block receptor
activation and/or signaling are becoming available for use in analysis
and/or treatment of tumors. The contribution of growth factors, such
as IGF-I, their receptors, binding proteins and signaling pathways in
the development and/or progression of tumors needs further
investigation.
Eicosanoids (prostaglandins) are another class of mediators that may
also contribute to prostate growth and differentiation. Expression of
the inducible form of one enzyme responsible for prostaglandin
synthesis, cyclooxygenase 2 (COX-2), has been observed in prostate
cancer. Pharmacologic inhibition of COX-2 activity induces apoptosis
in prostate cancer cells. Further, some prostaglandins act through the
peroxisome proliferator-activated receptor (PPAR), a member of the
nuclear hormone superfamily. The recent availability of COX-2
inhibitors and PPAR agonists will allow a sophisticated analysis of
their contributions to prostate growth and tumorigenesis.
Still other cytokines and growth factors, including interleukin (IL)-6,
members of the transforming growth factor (TGB)-beta family, and
others, have also been implicated in the development of prostate
cancer. New insights into the molecular mechanism(s) of action of such
factors through the cytokine receptor superfamily and transcription
factors such as the Smad proteins may have relevance to prostate growth
and or disease, as well.
While growth factors are extremely important in prostate function,
members of the nuclear hormone superfamily play crucial roles in
prostate development, growth, function, and tumorigenesis and/or
progression. Studies in developing prostate are of interest since
signaling pathways present at that time may have important implications
for later development of tumors. The receptors for the nuclear
receptor superfamily function primarily as transcription factors in the
nucleus to either suppress or activate gene expression through effects
on DNA transcription. At a recent NIDDK workshop entitled Co-
activators and Co-repressors in Gene Expression, work was presented
which suggested a role for the relative affinity of binding of nuclear
accessory proteins, including co-repressors and co-activators, to form
complexes essential to determining whether a particular gene is
activated or not in response to hormone. Further observations have
pointed to mutations in nuclear accessory proteins and/or nuclear
receptors as factors that can either cause hormone resistance or
inappropriate gene expression. Fusion proteins, which cause cancers,
such as the acute myelogenous leukemia-eight to twenty-one (AML-ETO)
fusion protein in acute myelogenous leukemia, recruit co-repressor
complexes to block gene transcription relevant to differentiation of
hematopoietic precursors. These factors have now become targets for
therapeutic intervention, as well. In addition, mutations in one co-
activator, known as AIB1, a member of the steroid receptor coactivator
(SRC)-1 family, have been implicated in breast cancer.
Androgens represent the primary steroid hormone affecting gene
expression in the prostate, though roles for estrogen and for orphan
nuclear receptors have also been suggested. Indeed, studies on the
newly discovered estrogen receptor (ER)-beta have revealed high levels
in prostate tissue, with the intriguing suggestion of a role(s) in
prostate development, as well as in prostate hyperplasia. Androgens
appear to form homodimer pairs in binding to chromatin, and recruit
nuclear accessory proteins, such as androgen receptor associated (ARA)
70 protein. The ARA is thus also a candidate for interaction with
other nuclear accessory proteins, such as co-activators or co-
repressors that regulate repression or activation of target genes.
Finally, orphan nuclear receptors--proteins structurally consistent
with nuclear receptors but for which no known hormone exists--have been
shown to have functions in prostate, as well (e.g., chicken ovalbumin
upstream transcription factor, or COUP-TF, and testis associated
receptor, or TR4). Another recent NIH Workshop on Selective Estrogen
Receptor Modulators (SERMS), focused on the potential utility of
hormonal analogs, partial agonists, and antagonists as therapeutic
agents for hormonal-dependent cancers, including those in breast and
prostate. Some of these Selective Receptor Modulators (SRM"s) have
already found their way into clinical use in the treatment and/or
prevention of breast cancer (e.g., Tamoxifen), and finasteride for
treatment of benign prostatic hypertrophy (BPH) and prostate cancer.
The role of SRMs, which can block the androgen effects on prostate
growth, tumor development and/or progression, remains to be determined.
Finally, the role of signal transduction cross talk between growth
factors and nuclear/orphan receptors may mediate interactions between
cell types in the prostate and contribute to stimulation and/or growth
of prostate and to tumorigenesis. This remains an important and
largely underdeveloped consideration in understanding the development
both of normal tissue and of disease, particularly in light of the fact
that tumors generally become androgen-independent. Additional studies
have suggested a role for environmental factors as well, and thus
understanding the overall concept of growth stimuli and growth controls
involved in this stage represents an important area in which further
investigation is needed.
Thus, the specific objectives of this research solicitation include but
are not limited to:
o Hormonal or growth factor regulation of prostate development,
function, growth, or tumor development
o Mechanism of action of nuclear hormones and/or peptide hormones or
growth factors in the regulation of prostate-specific gene expression
o Novel cell culture or transgenic model systems that allow for study
in vitro or in vivo of gene expression in prostate or prostate cells
o Role(s) of nuclear accessory proteins in regulation of hormone/growth
factor action in prostate
o Novel factor(s) associated with nuclear hormone action in prostate
involved in tumorigenesis
o Analogs, agonists, or antagonists of nuclear hormones/growth factors
with potential effects on tumor development and/or progression
o Orphan nuclear receptors with role(s) in prostate structure,
function, or disease development or progression
o Structural biology of the androgen receptor (AR) focusing on
interactions with other receptor interacting proteins, co-activators or
co-repressors, hormone, or hormone response elements
o Effects of Selective Receptor Modulators (SRM"s) on prostate
o Role(s) of heat shock, or other chaperone, proteins in regulating
androgen (and other hormone) function in prostate
o Signaling cross-talk between nuclear receptors and/or growth factor
or cytokine, and other cell surface receptors, and effects on
regulation of prostate gene expression and disease
initiation/progression
o Use of DNA arrays, bioinformatics approaches to proteomics, or in
silico methods of analysis to evaluate gene expression during growth
factor or hormone signaling among different cells in the prostate
during development, stages of tumor development, or tumor progression
o Age-related changes in hormone or growth factor signaling processes
and patterns of gene expression that may be involved in the increasing
risk of prostate cancer with age
o A mechanism of action of nuclear hormones working through non-
receptor-mediated events leading to the initiation of cancer in
prostate cells
o Role(s) of environmental factors that may interact with or influence
the effects of hormones and growth factors on prostate growth,
development, and/or tumor development
INCLUSION OF MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS
It is the policy of the NIH that members of minority groups and their
subpopulations must be included in all NIH supported biomedical and
behavioral research projects involving human subjects, unless a clear
and compelling rationale and justification is provided that inclusion
is inappropriate with respect to the health of the subjects or the
purpose of the research. This new policy results from the NIH
Revitalization Act of 1993 (Section 492B of Public Law 103-43).
All investigators proposing research involving human subjects should
read the "NIH Guidelines For Inclusion of Minorities as Subjects in
Clinical Research," which was published in the Federal Register of
March 28, 1994 (FR 59 14508-14513) and in the NIH Guide For Grants and
Contracts, Vol. 23, No. 11, March 18, 1994, available on the web at:
http://grants.nih.gov/grants/guide/notice-files/not94-100.html.
URLS IN NIH GRANT APPLICATIONS OR APPENDICES
All applications and proposals for NIH funding must be self-contained
within specified page limitations. Unless otherwise specified in an NIH
solicitation, internet addresses (URLs) should not be used to provide
information necessary to the review because reviewers are under no
obligation to view the Internet sites. Reviewers are cautioned that
their anonymity may be compromised when they directly access an
Internet site.
LETTER OF INTENT
Prospective applicants are asked to submit by February 27, 2001 a
letter of intent that includes a descriptive title of the proposed
research, the name, address, and telephone number of the Principal
Investigator, the identities of other key personnel and participating
institutions, and the number and title of the RFA in response to which
the application may be submitted.
Although a letter of intent is not required, is not binding, and does
not enter into the review of a subsequent application, the information
that it contains allows NIDDK staff to estimate the potential review
workload and plan the review.
The letter of intent is to be sent to:
Chief, Review Branch
Division of Extramural Activities, NIDDK
6707 Democracy Blvd., Room 653
Bethesda, MD 20892-5462
Bethesda, MD 20817 (for express/courier service)
Telephone: (301) 594-8885
FAX: (301) 480-3505
APPLICATION PROCEDURES
The research grant application form PHS 398 (rev. 4/98) is to be used
in applying for these grants. These forms are available at most
institutional offices of sponsored research and may be obtained from
the Division of Extramural Outreach and Information Resources, National
Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD
20892-7910, telephone 301-710-0267, email: GrantsInfo@nih.gov.
The modular grant concept establishes specific modules in which direct
costs may be requested as well as a maximum level for requested
budgets. Only limited budgetary information is required under this
approach. The just-in-time concept allows applicants to submit certain
information only when there is a possibility for an award. It is
anticipated that these changes will reduce the administrative burden
for the applicants, reviewers, and Institute staff. The research grant
application form PHS 398 (rev. 4/98) is to be used in applying for
these grants, with the modifications noted below.
BUDGET INSTRUCTIONS
General instructions for use of the modular grant format include:
Modular Grant applications will request direct costs in $25,000
modules, up to a total direct cost request of $225,000 per year for R01
applications, or $100,000 for R21 applications. The total direct costs
must be requested in accordance with the program guidelines and the
modifications made to the standard PHS 398 application instructions
described below, and as noted in the NIH Guide announcement for modular
grants (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-046.html):
FACE PAGE: Items 7a and 7b should be completed, indicating Direct Costs
(in $25,000 increments up to a maximum of $225,000 or $100,000) and
Total Costs [Modular Total Direct plus Facilities and Administrative
(F&A) costs] for the initial budget period. Items 8a and 8b should be
completed indicating the Direct and Total Costs for the entire proposed
period of support.
o DETAILED BUDGET FOR THE INITIAL BUDGET PERIOD: Do not complete Form
Page 4 of the PHS 398. It is not required and will not be accepted with
the application.
o BUDGET FOR THE ENTIRE PROPOSED PERIOD OF SUPPORT: Do not complete
the categorical budget table on Form Page 5 of the PHS 398. It is not
required and will not be accepted with the application.
o NARRATIVE BUDGET JUSTIFICATION: Prepare a Modular Grant Budget
Narrative page. (See
http://grants.nih.gov/grants/funding/modular/modular.htm for sample
pages.) At the top of the page, enter the total direct costs requested
for each year. This is not a Form page.
o Under Personnel, list ALL project personnel, including their names,
percent of effort, and roles on the project. No individual salary
information should be provided. However, the applicant should use the
NIH appropriation language salary cap and the NIH policy for graduate
student compensation in developing the budget request.
For Consortium/Contractual costs, provide an estimate of total costs
(direct plus facilities and administrative) for each year, each rounded
to the nearest $1,000. List the individuals/organizations with whom
consortium or contractual arrangements have been made, the percent
effort of key personnel, and the role on the project. Indicate whether
the collaborating institution is foreign or domestic. The total cost
for a consortium/contractual arrangement is included in the overall
requested modular direct cost amount. Include the Letter of Intent to
establish a consortium. Indirect costs for subcontracts are included
in the total costs for the application and should also be in modular
form. Provide an additional narrative budget justification for any
variation in the number of modules requested.
o BIOGRAPHICAL SKETCH: The Biographical Sketch provides information
used by reviewers in the assessment of each individual"s qualifications
for a specific role in the proposed project, as well as to evaluate the
overall qualifications of the research team. A biographical sketch is
required for all key personnel, following the instructions below. No
more than three pages may be used for each person. A sample
biographical sketch may be viewed at:
http://grants.nih.gov/grants/funding/modular/modular.htm.
- Complete the educational block at the top of the form page,
- List position(s) and any honors,
- Provide information, including overall goals and responsibilities, on
research projects ongoing or completed during the last three years.
- List selected peer-reviewed publications, with full citations.
o CHECKLIST: This page should be completed and submitted with the
application. If the F&A rate agreement has been established, indicate
the type of agreement and the date. All appropriate exclusions must be
applied in the calculation of the F&A costs for the initial budget
period and all future budget years.
o The applicant should provide the name and phone number of the
individual to contact concerning fiscal and administrative issues if
additional information is necessary following the initial review.
Applicants should carefully read the specific text of this RFA for
budgetary constraints applying to this particular initiative.
The RFA label available in the PHS 398 (rev. 4/98) application form
must be affixed to the bottom of the face page of the application.
Failure to use this label could result in delayed processing of the
application such that it may not reach the review committee in time for
review. In addition, the RFA title and number must be typed on line 2
of the face page of the application form and the YES box must be
marked.
The sample RFA available at:
http://grants.nih.gov/grants/funding/phs398/label-bk.pdf has been modified
to allow for this change. Please note this is in pdf format.
Submit a signed, typewritten original of the application, including the
Checklist, and three signed photocopies, in one package to:
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040 - MSC 7710
Bethesda, MD 20892-7710
Bethesda, MD 20817 (for express/courier service)
At time of submission, two additional copies of the application must be
sent to:
Chief, Review Branch
6707 Democracy Blvd., Room 653
Division of Extramural Activities, NIDDK
Bethesda, MD 20892-5452
Bethesda, MD 20817 (for express/courier service)
Applications must be received by March 27, 2001. If an application is
received after that date, it will be returned to the applicant without
review. Similarly, supplemental documents containing significant
revision or additions will not be accepted after that date, unless
applicants are notified by the Scientific Review Administrator. The
Center for Scientific Review (CSR) will not accept any application in
response to this RFA that is essentially the same as one currently
pending initial review, unless the applicant withdraws the pending
application. The CSR will not accept any application that is
essentially the same as one already reviewed.
REVIEW CONSIDERATIONS
Applications that are complete and responsive to the RFA will be
evaluated for scientific and technical merit by an appropriate peer
review group (special emphasis panel) convened by the NIDDK in
accordance with the review criteria stated below. As part of the
initial merit review, all applications will receive a written critique
and undergo a process in which only those applications deemed to have
the highest scientific merit, generally the top half of the
applications under review, will be discussed, assigned a priority
score, and receive a second level review by the National Diabetes and
Digestive and Kidney Diseases Advisory Council.
Review Criteria
The goals of NIH-supported research are to advance our understanding of
biological systems, improve the control of disease, and enhance health.
In the written comments, reviewer will be asked to discuss the
following aspects of the application in order to judge the likelihood
that the proposed research will have a substantial impact on the
pursuit of these goals. Each of these criteria will be addressed and
considered in assigning the overall score, weighting them as
appropriate for each application. Note that the application does not
need to be strong in all categories to be judged likely to have major
scientific impact and thus deserve a high priority score. For example,
an investigator may propose to carry out important work that by its
nature is not innovative but is essential to move a field forward.
o Significance: Does this study address an important problem? If the
aims of the application are achieved, how will scientific knowledge be
advanced? What will be the effect of these studies on the concepts or
methods that drive this field?
o Approach: Are the conceptual framework, design, methods, and
analyses adequately developed, well-integrated, and appropriate to the
aims of the project? Does the applicant acknowledge potential problem
areas and consider alternative tactics?
o Innovation: Does the project employ novel concepts, approaches or
method? Are the aims original and innovative? Does the project
challenge existing paradigms or develop new methodologies or
technologies?
o Investigator: Is the investigator appropriately trained and well
suited to carry out this work? Is the work proposed appropriate to the
experience level of the principal investigator and other researchers
(if any)?
o Environment: Does the scientific environment in which the work will
be done contribute to the probability of success? Do the proposed
experiments take advantage of unique features of the scientific
environment or employ useful collaborative arrangements? Is there
evidence of institutional support?
In addition to the above criteria, in accordance with NIH policy, all
applications will also be reviewed with respect to the following:
o Adequacy of plans to include minorities and their subgroups, as
appropriate for the scientific goals of the research. Plans for the
recruitment and retention of subjects will also be evaluated.
o The reasonableness of the proposed budget and duration to the
proposed research.
o The adequacy of the proposed protection of humans, animals, or the
environment, to the extent that they may be adversely affected by the
project proposed in the application.
For applicants from foreign institutions:
o Availability of special opportunities for furthering research
programs through the use of unusual talent resources, populations, or
environmental conditions in other countries which are not readily
available in the United States or which provide augmentation of
existing U.S. resources.
AWARD CRITERIA
The anticipated date of award is September 28, 2001.
Award criteria that will be used to make award decisions include:
o Scientific merit as determined by peer review,
o Availability of funds,
o Programmatic priorities.
INQUIRIES
Inquiries concerning this RFA are encouraged. The opportunity to
clarify any issues or questions from potential applicants is welcomed.
Direct inquiries regarding programmatic issues relevant to NIDDK to:
Ronald Margolis, Ph.D.
Senior Advisor, Molecular Endocrinology
Division of Diabetes, Endocrinology, and Metabolic Diseases
NIDDK
6707 Democracy Blvd.
Room 6107
Bethesda, MD 20892-5460
Telephone: (301) 594-8819
FAX: 301-435-6047
E-mail: rm76f@nih.gov
Monica Liebert, Ph.D.
Director, Basic Science Programs in Urology
Division of Kidney, Urology and Hematology
NIDDK
6707 Democracy Blvd.
Room 623
Bethesda, MD 20892-5460
Telephone: (301) 594-1409
FAX: 301-480-3510
E-mail: LiebertM@extra.niddk.nih.gov
Direct inquiries regarding fiscal and administrative matters to:
Cheryl Chick
Grants Management Specialist
Division of Extramural Activities
NIDDK
Bethesda, MD 20892-5460
Telephone: (301) 594-8825
FAX: (301) 594-3504
E-mail: ChickC@extra.niddk.nih.gov
Trude Hilliard
Grants Management Specialist
Division of Extramural Activities
NIDDK
Bethesda, MD 20892-5460
Telephone: (301) 594-8859
FAX: (301) 594-3504
E-mail: HilliardT@extra.niddk.nih.gov
Direct inquiries regarding programmatic issues relevant to NIA to:
Frank Bellino, PhD
Deputy Associate Director
Endocrinology Program Administrator
Biology of Aging Program
National Institute on Aging
Gateway Bldg., Suite 2C231
Bethesda, MD 20892-9205
Telephone: (301) 496-6402
FAX: (301) 402-0010
E-mail: bellinof@exmur.nia.nih.gov
Direct inquiries regarding fiscal and administrative matters to:
Crystal Ferguson
Grants Management Office
National Institute on Aging
Gateway Building, Suite 2N212
Bethesda, MD 20892-9205
Telephone: (301) 496-1472
FAX: (301) 402-3672
Email: fergusoc@exmur.nia.nih.gov
Direct inquiries regarding programmatic issues relevant to NCI to:
Suresh Mohla, Ph.D.
Chief, Tumor Biology and Metastasis Branch
Division of Cancer Biology
National Cancer Institute
6130 Executive Boulevard
EPN Suite 5000
Rockville MD 20892-7364
Telephone : (301) 435-1878
FAX : (301) 480-0864
Email: sm82e@nih.gov
Direct inquiries regarding fiscal and administrative matters to:
Ms. Crystal Wolfrey
Lead Grants Management Specialist
Grants Administration Branch
National Cancer Institute
Executive Plaza South, Room 243
6120 Executive Blvd., MSC 7150
Rockville, Maryland 20892-7150
Telephone: (301) 496-8634
FAX: (301) 496-8601
Email: wolfreyc@mail.nih.gov
Direct inquiries regarding programmatic issues relevant to NIEHS to:
Michael E. McClure, Ph.D.
Chief, Organs and Systems Toxicology Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences, NIH
111 T.W. Alexander Drive
Courier: 79 T.W. Alexander Dr
P.O. Box 12233, Mail Drop EC-23
Bldg. 4401, Rm. 3417
Research Triangle Park, North Carolina 27709
RTP. NC 27709
Telephone: (919) 541-5327
FAX: (919) 541-5064
E-Mail: mm461n@nih.gov
Direct inquiries regarding fiscal and administrative matters to:
Dorothy Duke
Division of Extramural Research and Training
National Institute of Environmental Health Science
Box 12233, MD EC-22
Research Triangle Park, NC 27709
Telephone: (919) 541-1373
FAX: (919) 541-2860
Email: Duke3@niehs.nih.gov
AUTHORITY AND REGULATIONS
This program is described in the Catalog of Federal Domestic Assistance
No. 93.847 for DEM and 93-848 for KUH, No. 93.866 for NIA, No. 93.394
for NCI, and No. 93.113 and 93.866. Awards are made under
authorization of the Public Health Service Act, Title IV, Part A
(Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and
285) and administered under NIH grants policies and Federal Regulations
42 CFR 52 and 45 CFR Part 74. This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or
Health Systems Agency review.
The NIH strongly encourages all grant and contract recipients to
provide a smoke-free workplace and promote the non-use of all tobacco
products. In addition, Public Law 103-227, the Pro-Children Act of
1994, prohibits smoking in certain facilities (or in some cases, any
portion of a facility) in which regular or routine education, library,
day care, health care or early childhood development services are
provided to children. This is consistent with the NIH mission to
protect and advance the physical and mental health of the American
people.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
| ||||||
|
|
|
Department of Health and Human Services (HHS) |
|
|||
|
NIH... Turning Discovery Into Health® |
||||||